KTTA vs LBRX

Pasithea Therapeutics Corp. vs LB Pharmaceuticals Inc — Valuation Comparison 2026

KTTA

Biotechnology
Pasithea Therapeutics Corp.
Quality
4.1
out of 10
Value Trap
24
SAFE
Price
$0.70
Last close
Models
7/13
Active
VS

LBRX

Biotechnology
LB Pharmaceuticals Inc
Quality
4.6
out of 10
Value Trap
Price
$27.53
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType KTTA Fair ValueKTTA Upside LBRX Fair ValueLBRX Upside
Bayesian DCF Intrinsic $1.01 +45.1% $11.21 -59.3%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.72 +147.3% $8.72 -68.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for KTTA vs LBRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KTTA vs LBRX — Which Stock Is More Undervalued?

LBRX scores higher with a 4.6/10 quality rating vs KTTA's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Pasithea Therapeutics Corp. (KTTA) and LB Pharmaceuticals Inc (LBRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KTTA currently trades at $0.70 with a QOC of 4.1/10, while LBRX trades at $27.53 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).